<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824512</url>
  </required_header>
  <id_info>
    <org_study_id>2-39-00240-133</org_study_id>
    <secondary_id>2007-005371-34</secondary_id>
    <nct_id>NCT00824512</nct_id>
  </id_info>
  <brief_title>Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia</brief_title>
  <official_title>A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus
      placebo in patients suffering from Friedreich Ataxia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Creatine Rephosphorylation Rate Post Exercise</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Creatine Rephosphorylation Rate post exercise measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated with correction according to muscular pH.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Post Exercise Perfusion</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Peak post exercise perfusion (mL/mn/100 g of tissue) was assessed using Arterial spin labelling combined with Nuclear Magnetic Resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Perfusion</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perfusion-time Integral During the First 9 Minutes Post Exercise.</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The integral of 'peak perfusion' over a period of 9 minutes post exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Reoxygenation Rate Post Exercise.</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Muscle reoxygenation rate post exercise was assessed using Myoglobin Hydrogen-1 Nuclear Magnetic Resonance spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Trophicity: Maximum Cross Section of Muscle</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Muscle trophicity measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated based on maximum cross section of muscle (cm^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developed Force During the Exercise Bout</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Developed force during the exercise bout measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalised Work Developed During the Exercise</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Normalised work developed during the exercise was derived as Work developed during the exercise/([60 X Maximum cross section of muscle]-1100).
Normalised work measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolism Efficacy Index</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The metabolism efficacy index was derived as Normalised work x creatine phosphorylation rate (sec-1). [Normalised work was derived as Work developed during the exercise/(60 X Maximum cross section of muscle-1100)]. Greater values of Metabolism Efficacy index indicate improvement in skeletal muscle energetics while lower values indicate the reverse. Negative values obtained using the formula indicated severe levels of muscle weakness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Cooperative Ataxia Rating Scale [ICARS] (Total Score)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales (i.e. Posture and gait disturbances, Kinetic functions, Speech disorders, &amp; Oculomotor disorders). Scores for each subscale quantify the extent of ataxia in each clinically important area and subscale scores are also summed to give a total score ranging from 0 to 100, with 100 indicative of the most severely affected outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICARS (Posture and Gait Disturbance Score)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Posture and gait disturbances. Posture and gait disturbances score range from 0 to 34 (Higher scores indicate higher levels of impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICARS (Kinetic Function Score)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Kinetic Function. Kinetic Function score range from 0 to 52 (Higher scores indicate higher levels of impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICARS (Speech Disorders Score)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Speech Disorders. Speech Disorders Score range from 0 to 8 (Higher scores indicate higher levels of impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICARS (Oculomotor Disorders Score)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Oculomotor Disorders. Oculomotor Disorders score range from 0 to 6 (Higher scores indicate higher levels of impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25-foot Walk Test</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine Hole Peg Test (Dominant Hand)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine Hole Peg Test (Nondominant Hand)</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choice Reaction Time Test- Reaction Time</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choice Reaction Time Test- Movement Time</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Assessment Scale (VAS) of Global Impression - Patient</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Assessment Scale (VAS) of Global Impression - Parents</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Assessment Scale (VAS) of Global Impression - Investigator</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>EGb 761® 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGb 761 120 mg</intervention_name>
    <description>EGb 761® 120 mg bid, orally for 12 to 14 weeks</description>
    <arm_group_label>EGb 761® 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet BID, orally for 12 to 14 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Friedreich ataxia diagnosis confirmed by evidenced mutation expansion of Frataxin gene

          -  Ambulatory patient, with depressed tendon reflexes and pyramidal syndrome associated
             or not to a loss of position or vibration senses or dysarthria

          -  Patient able to perform the tests of the study

        Exclusion Criteria:

          -  Severe cardiac disease as assessed by echocardiography performed at least within 6
             months before screening or during the wash out period (4 weeks)

          -  Absolute contra-indication to Nuclear Magnetic Resonance spectroscopy(NMR)
             examination: iron and any magnetic objects implanted in the whole body, e.g. some
             neurostimulators, cardiac pace-makers, vascular clips and other implanted orthopaedic
             prosthesis

          -  Patient who did not deplete at baseline phosphocreatine (PCr) pool by more than 30 %
             during the exercise bout

          -  Any continuous use of the following forbidden medications:

          -  other antioxidant such as idebenone, coenzyme Q, vitamin E/C taken for less than 4
             weeks prior study treatment start (ie for antioxidant drugs a mandatory wash-out
             period of 4 weeks prior study drug start has to be observed),

          -  any other vasodilators

          -  tranquilizer such as benzodiazepine, meprobamate or buspirone, and/or antidepressant
             (only one), at non stable dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécile Merdrignac, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>October 30, 2012</results_first_submitted>
  <results_first_submitted_qc>April 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2013</results_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at a single centre investigational site in France.</recruitment_details>
      <pre_assignment_details>Overall number of baseline participants differs from number of participants who started as efficacy analysis was performed on modified Intention-To-Treat (mITT) population (i.e. 21 patients). 1 patient in the placebo group did not meet the primary criteria and thus excluded from the analysis. No patient was excluded from the safety population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EGb 761® 120 mg</title>
          <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EGb 761® 120 mg</title>
          <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.
Baseline Characteristics data is based on the mITT population, which comprised of the 21 patients. One patient in the placebo group was excluded from the analyses because no assessment of the primary criteria was performed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>12-15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16-22 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration since first symptoms</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="B2" value="7.7" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="B3" value="7.8" lower_limit="3" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of repeats of Guanine Adenine Adenine (GAA) sequence</title>
          <units>GAA sequence repetitions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="700" lower_limit="500" upper_limit="950"/>
                    <measurement group_id="B2" value="810" lower_limit="100" upper_limit="1000"/>
                    <measurement group_id="B3" value="700" lower_limit="100" upper_limit="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Creatine Rephosphorylation Rate Post Exercise</title>
        <description>Creatine Rephosphorylation Rate post exercise measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated with correction according to muscular pH.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatine Rephosphorylation Rate Post Exercise</title>
          <description>Creatine Rephosphorylation Rate post exercise measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated with correction according to muscular pH.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>pH per second</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" lower_limit="0.013" upper_limit="0.037"/>
                    <measurement group_id="O2" value="0.029" lower_limit="0.018" upper_limit="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" lower_limit="0.015" upper_limit="0.043"/>
                    <measurement group_id="O2" value="0.029" lower_limit="0.014" upper_limit="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="-0.009" upper_limit="0.009"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.013" upper_limit="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9133</p_value>
            <p_value_desc>No multiplicity adjustment performed for this study and all statistical tests are two-sided at the 5% significance level.</p_value_desc>
            <method>Non parametric ANCOVA on the rank test</method>
            <method_desc>The baseline value was used as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Post Exercise Perfusion</title>
        <description>Peak post exercise perfusion (mL/mn/100 g of tissue) was assessed using Arterial spin labelling combined with Nuclear Magnetic Resonance imaging.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Post Exercise Perfusion</title>
          <description>Peak post exercise perfusion (mL/mn/100 g of tissue) was assessed using Arterial spin labelling combined with Nuclear Magnetic Resonance imaging.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>ml/mn/100 g of tissue</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.30" lower_limit="33.9" upper_limit="91.0"/>
                    <measurement group_id="O2" value="51.80" lower_limit="10.8" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.80" lower_limit="37.6" upper_limit="88.8"/>
                    <measurement group_id="O2" value="46.60" lower_limit="30.7" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" lower_limit="-29.5" upper_limit="31.2"/>
                    <measurement group_id="O2" value="-1.55" lower_limit="-20.9" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Perfusion</title>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Perfusion</title>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.30" lower_limit="0.8" upper_limit="269.3"/>
                    <measurement group_id="O2" value="58.55" lower_limit="5.3" upper_limit="317.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.80" lower_limit="0.8" upper_limit="119.3"/>
                    <measurement group_id="O2" value="76.55" lower_limit="0.8" upper_limit="384.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" lower_limit="-267.0" upper_limit="94.5"/>
                    <measurement group_id="O2" value="14.25" lower_limit="-232.5" upper_limit="274.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perfusion-time Integral During the First 9 Minutes Post Exercise.</title>
        <description>The integral of 'peak perfusion' over a period of 9 minutes post exercise.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Perfusion-time Integral During the First 9 Minutes Post Exercise.</title>
          <description>The integral of 'peak perfusion' over a period of 9 minutes post exercise.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>mL/100 g of tissue</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.90" lower_limit="83.6" upper_limit="353.0"/>
                    <measurement group_id="O2" value="157.20" lower_limit="11.8" upper_limit="373.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.60" lower_limit="86.1" upper_limit="417.3"/>
                    <measurement group_id="O2" value="185.70" lower_limit="22.0" upper_limit="396.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.20" lower_limit="-138.2" upper_limit="237.4"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-156.7" upper_limit="212.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Reoxygenation Rate Post Exercise.</title>
        <description>Muscle reoxygenation rate post exercise was assessed using Myoglobin Hydrogen-1 Nuclear Magnetic Resonance spectroscopy.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Reoxygenation Rate Post Exercise.</title>
          <description>Muscle reoxygenation rate post exercise was assessed using Myoglobin Hydrogen-1 Nuclear Magnetic Resonance spectroscopy.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>per second</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0870" lower_limit="0.035" upper_limit="0.156"/>
                    <measurement group_id="O2" value="0.0540" lower_limit="0.024" upper_limit="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0580" lower_limit="0.030" upper_limit="0.114"/>
                    <measurement group_id="O2" value="0.0620" lower_limit="0.021" upper_limit="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0350" lower_limit="-0.124" upper_limit="0.039"/>
                    <measurement group_id="O2" value="-0.0035" lower_limit="-0.058" upper_limit="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Trophicity: Maximum Cross Section of Muscle</title>
        <description>Muscle trophicity measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated based on maximum cross section of muscle (cm^2)</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Trophicity: Maximum Cross Section of Muscle</title>
          <description>Muscle trophicity measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy and calculated based on maximum cross section of muscle (cm^2)</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>cm^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.10" lower_limit="16.6" upper_limit="33.1"/>
                    <measurement group_id="O2" value="28.95" lower_limit="23.4" upper_limit="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="16.7" upper_limit="33.2"/>
                    <measurement group_id="O2" value="29.85" lower_limit="24.0" upper_limit="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-1.3" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.55" lower_limit="-2.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Developed Force During the Exercise Bout</title>
        <description>Developed force during the exercise bout measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Developed Force During the Exercise Bout</title>
          <description>Developed force during the exercise bout measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>Joules</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.30" lower_limit="177.0" upper_limit="822.9"/>
                    <measurement group_id="O2" value="358.10" lower_limit="207.2" upper_limit="1172.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.50" lower_limit="136.90" upper_limit="750.9"/>
                    <measurement group_id="O2" value="354.35" lower_limit="200.9" upper_limit="1002.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.40" lower_limit="-146.9" upper_limit="56.6"/>
                    <measurement group_id="O2" value="19.20" lower_limit="-191.8" upper_limit="109.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalised Work Developed During the Exercise</title>
        <description>Normalised work developed during the exercise was derived as Work developed during the exercise/([60 X Maximum cross section of muscle]-1100).
Normalised work measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Normalised Work Developed During the Exercise</title>
          <description>Normalised work developed during the exercise was derived as Work developed during the exercise/([60 X Maximum cross section of muscle]-1100).
Normalised work measured using Phosphorus 31 Nuclear Magnetic Resonance (P-31 NMR)spectroscopy.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>Joules/cm^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.07" lower_limit="6.3" upper_limit="26.0"/>
                    <measurement group_id="O2" value="12.00" lower_limit="8.6" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.23" lower_limit="7.6" upper_limit="24.0"/>
                    <measurement group_id="O2" value="11.53" lower_limit="6.1" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" lower_limit="-6.3" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.47" lower_limit="-4.8" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolism Efficacy Index</title>
        <description>The metabolism efficacy index was derived as Normalised work x creatine phosphorylation rate (sec-1). [Normalised work was derived as Work developed during the exercise/(60 X Maximum cross section of muscle-1100)]. Greater values of Metabolism Efficacy index indicate improvement in skeletal muscle energetics while lower values indicate the reverse. Negative values obtained using the formula indicated severe levels of muscle weakness.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolism Efficacy Index</title>
          <description>The metabolism efficacy index was derived as Normalised work x creatine phosphorylation rate (sec-1). [Normalised work was derived as Work developed during the exercise/(60 X Maximum cross section of muscle-1100)]. Greater values of Metabolism Efficacy index indicate improvement in skeletal muscle energetics while lower values indicate the reverse. Negative values obtained using the formula indicated severe levels of muscle weakness.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>per second</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0180" lower_limit="-0.042" upper_limit="0.038"/>
                    <measurement group_id="O2" value="0.0150" lower_limit="0.010" upper_limit="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0130" lower_limit="-0.021" upper_limit="0.042"/>
                    <measurement group_id="O2" value="0.0145" lower_limit="0.007" upper_limit="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0010" lower_limit="-0.021" upper_limit="0.021"/>
                    <measurement group_id="O2" value="-0.0010" lower_limit="-0.007" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Cooperative Ataxia Rating Scale [ICARS] (Total Score)</title>
        <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales (i.e. Posture and gait disturbances, Kinetic functions, Speech disorders, &amp; Oculomotor disorders). Scores for each subscale quantify the extent of ataxia in each clinically important area and subscale scores are also summed to give a total score ranging from 0 to 100, with 100 indicative of the most severely affected outcome.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>International Cooperative Ataxia Rating Scale [ICARS] (Total Score)</title>
          <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales (i.e. Posture and gait disturbances, Kinetic functions, Speech disorders, &amp; Oculomotor disorders). Scores for each subscale quantify the extent of ataxia in each clinically important area and subscale scores are also summed to give a total score ranging from 0 to 100, with 100 indicative of the most severely affected outcome.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="21" upper_limit="54"/>
                    <measurement group_id="O2" value="26.5" lower_limit="20" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="26" upper_limit="60"/>
                    <measurement group_id="O2" value="29.0" lower_limit="22" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-9" upper_limit="6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-4" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICARS (Posture and Gait Disturbance Score)</title>
        <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Posture and gait disturbances. Posture and gait disturbances score range from 0 to 34 (Higher scores indicate higher levels of impairment).</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ICARS (Posture and Gait Disturbance Score)</title>
          <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Posture and gait disturbances. Posture and gait disturbances score range from 0 to 34 (Higher scores indicate higher levels of impairment).</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="8" upper_limit="29"/>
                    <measurement group_id="O2" value="12.5" lower_limit="7" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="10" upper_limit="32"/>
                    <measurement group_id="O2" value="12.0" lower_limit="10" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-6" upper_limit="3"/>
                    <measurement group_id="O2" value="2.8" lower_limit="-3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICARS (Kinetic Function Score)</title>
        <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Kinetic Function. Kinetic Function score range from 0 to 52 (Higher scores indicate higher levels of impairment).</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ICARS (Kinetic Function Score)</title>
          <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Kinetic Function. Kinetic Function score range from 0 to 52 (Higher scores indicate higher levels of impairment).</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O2" value="13.0" lower_limit="11" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6" upper_limit="5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICARS (Speech Disorders Score)</title>
        <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Speech Disorders. Speech Disorders Score range from 0 to 8 (Higher scores indicate higher levels of impairment).</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ICARS (Speech Disorders Score)</title>
          <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Speech Disorders. Speech Disorders Score range from 0 to 8 (Higher scores indicate higher levels of impairment).</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-3" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICARS (Oculomotor Disorders Score)</title>
        <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Oculomotor Disorders. Oculomotor Disorders score range from 0 to 6 (Higher scores indicate higher levels of impairment).</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ICARS (Oculomotor Disorders Score)</title>
          <description>The ICARS was used to measure the general clinical symptoms of Friedreich ataxia using four subscales including Oculomotor Disorders. Oculomotor Disorders score range from 0 to 6 (Higher scores indicate higher levels of impairment).</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed 25-foot Walk Test</title>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Timed 25-foot Walk Test</title>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" lower_limit="6.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="6.75" lower_limit="5.0" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="7.0" upper_limit="15.5"/>
                    <measurement group_id="O2" value="6.75" lower_limit="5.5" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-2.5" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nine Hole Peg Test (Dominant Hand)</title>
        <description>The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Nine Hole Peg Test (Dominant Hand)</title>
          <description>The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.50" lower_limit="31.5" upper_limit="71.5"/>
                    <measurement group_id="O2" value="43.50" lower_limit="33.5" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.00" lower_limit="29.5" upper_limit="86.0"/>
                    <measurement group_id="O2" value="40.75" lower_limit="32.0" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="-2.5" upper_limit="15.5"/>
                    <measurement group_id="O2" value="-1.50" lower_limit="-4.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nine Hole Peg Test (Nondominant Hand)</title>
        <description>The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Nine Hole Peg Test (Nondominant Hand)</title>
          <description>The nine hole peg test was used to assess cognitive function and in particular, fine motor coordination. The patient was asked to place nine pegs in nine holes and was scored on the amount of time it took to place and remove all nine pegs.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.50" lower_limit="39.5" upper_limit="113.0"/>
                    <measurement group_id="O2" value="48.50" lower_limit="34.5" upper_limit="117.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.00" lower_limit="36.0" upper_limit="113.5"/>
                    <measurement group_id="O2" value="46.50" lower_limit="36.5" upper_limit="100.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="-11.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.75" lower_limit="-17.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Choice Reaction Time Test- Reaction Time</title>
        <description>The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Choice Reaction Time Test- Reaction Time</title>
          <description>The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>millisecond</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513.5" lower_limit="392" upper_limit="1594"/>
                    <measurement group_id="O2" value="536.0" lower_limit="461" upper_limit="692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491.0" lower_limit="417" upper_limit="899"/>
                    <measurement group_id="O2" value="531.0" lower_limit="446" upper_limit="865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="-1032" upper_limit="40"/>
                    <measurement group_id="O2" value="9.0" lower_limit="-89" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Choice Reaction Time Test- Movement Time</title>
        <description>The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Choice Reaction Time Test- Movement Time</title>
          <description>The choice reaction time test was used to assess cognitive functioning. On random presentation of one of six signal lights, the patient was asked to respond as quickly and accurately as possible by removing their index finger of the dominant hand from the bottom key and pressing whichever of the top six keys was indicated by the signal. Reaction time was the time elapsed between the presentation of the stimulus and the release of the finger and movement time was defined as the time elapsed between release of the finger and pressure of the second key.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>millisecond</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="561.5" lower_limit="344" upper_limit="1452"/>
                    <measurement group_id="O2" value="531.0" lower_limit="390" upper_limit="986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555.0" lower_limit="406" upper_limit="1107"/>
                    <measurement group_id="O2" value="496.5" lower_limit="396" upper_limit="1419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="-998" upper_limit="190"/>
                    <measurement group_id="O2" value="-31.0" lower_limit="-124" upper_limit="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Assessment Scale (VAS) of Global Impression - Patient</title>
        <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Assessment Scale (VAS) of Global Impression - Patient</title>
          <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="O2" value="68.5" lower_limit="12" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" lower_limit="12" upper_limit="82"/>
                    <measurement group_id="O2" value="63.0" lower_limit="26" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-47" upper_limit="30"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-20" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Assessment Scale (VAS) of Global Impression - Parents</title>
        <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Assessment Scale (VAS) of Global Impression - Parents</title>
          <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="45" upper_limit="96"/>
                    <measurement group_id="O2" value="62.0" lower_limit="16" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="31" upper_limit="95"/>
                    <measurement group_id="O2" value="57.0" lower_limit="11" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-14" upper_limit="13"/>
                    <measurement group_id="O2" value="-10.0" lower_limit="-25" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Assessment Scale (VAS) of Global Impression - Investigator</title>
        <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
        <time_frame>Baseline (Week 0) to Week 12</time_frame>
        <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 761® 120 mg</title>
            <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Assessment Scale (VAS) of Global Impression - Investigator</title>
          <description>The VAS used a 10-cm scoring scale in which values were reported in mm such that 0=bad and 100=good. Total score range on VAS is from 0 to 100.</description>
          <population>Due to small sample size and considering there are no specific studies in this population with EGb761; calculation with the use of a statistical hypothesis was not possible. Primary efficacy analyses performed on the mITT population and analysis of safety performed on the safety population.</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="67" upper_limit="90"/>
                    <measurement group_id="O2" value="76.0" lower_limit="25" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="46" upper_limit="87"/>
                    <measurement group_id="O2" value="74.0" lower_limit="46" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Week 0) to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-36" upper_limit="13"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-23" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EGb 761® 120 mg</title>
          <description>EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.
Baseline Characteristics data is based on the mITT population, which comprised of the 21 patients. One patient in the placebo group was excluded from the analyses because no assessment of the primary criteria was performed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Orthopedic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Primary Care</name_or_title>
      <organization>Ipsen</organization>
      <phone>clinical.trials@ipsen.com</phone>
      <email>clinical.trials@ipsen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

